secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-266866
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx Q3 2025 net loss widens to $55.8M; collaboration revenue drops 81%
--------------------------------------------------------------------------

- Cash, equivalents, and marketable securities of $576.0M as of Sep 30, 2025; expected to fund operations into 2028.
- Collaboration revenue fell to $4.9M from $26.0M YoY, driven by completion of anito-cel dosing in iMMagine-1 trial.
- R&D expenses decreased to $35.1M from $39.2M YoY; G&A expenses rose to $31.6M from $20.5M YoY on commercial readiness costs.
- Net loss was $55.8M compared to $25.9M in Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312525266866/0001193125-25-266866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312525266866/aclx-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-266866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer